Genome

Qihan Biotech Announces Publication in Microbiology Spectrum on CRISPR-Cas Multiplexed Genome Editing for Reducing African Swine Fever Virus

Retrieved on: 
Tuesday, June 18, 2024

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced its groundbreaking research titled "Testing Multiplexed anti-ASFV CRISPR-Cas9 in Reducing African Swine Fever Virus" in Microbiology Spectrum, an academic journal of the American Society for Microbiology.

Key Points: 
  • Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced its groundbreaking research titled "Testing Multiplexed anti-ASFV CRISPR-Cas9 in Reducing African Swine Fever Virus" in Microbiology Spectrum, an academic journal of the American Society for Microbiology.
  • The study indicates that the long-term expression of CRISPR-Cas, specifically targeting the pathogen genome in living organisms, holds promise as an effective method to inhibit the replication and infection of the African Swine Fever Virus (ASFV).
  • In live animal pathogen challenge experiments, the transgenic pigs demonstrated a certain level of resistance to African Swine Fever.
  • This study assessed and enhanced pigs' resistance to African Swine Fever Virus (ASFV) infection, providing valuable insights for future antiviral immune strategies in agriculture and livestock farming.

Dovetail Genomics and AGRF Announce Transformative Partnership Set to Advance Genomic Research in Australasia

Retrieved on: 
Monday, June 24, 2024

SCOTTS VALLEY, Calif. and MELBOURNE, Australia, June 24, 2024 /PRNewswire/ -- Dovetail Genomics, a pioneering leader in the development of genomic solutions, today announced a new strategic partnership with Australian Genome Research Facility (AGRF). As Australia's premier nonprofit genomic sequencing service provider, AGRF powers genomics through a national network of services and expertise. This collaboration is aimed at bolstering genomic research and innovation across Australia and New Zealand, launching AGRF as the premier provider of Dovetail's cutting-edge products and services in the Australasian market.

Key Points: 
  • As Australia's premier nonprofit genomic sequencing service provider, AGRF powers genomics through a national network of services and expertise.
  • This collaboration is aimed at bolstering genomic research and innovation across Australia and New Zealand, launching AGRF as the premier provider of Dovetail's cutting-edge products and services in the Australasian market.
  • Under this partnership, AGRF will offer Dovetail's comprehensive 3D genomic portfolio of proximity ligation-based products, including Dovetail® Omni-C®, Micro-C, and the new family of LinkPrep™ Technology based products, TopoLink™, AssemblyLink™, and VariLink™ Kits.
  • By joining forces with AGRF, Dovetail Genomics underscores its commitment to expanding its global footprint and supporting the scientific community with advanced genomic solutions.

SQUID pries open AI black box

Retrieved on: 
Friday, June 21, 2024

While these genomic insights may appear helpful, scientists aren't sure how today's AI models come to their conclusions in the first place.

Key Points: 
  • While these genomic insights may appear helpful, scientists aren't sure how today's AI models come to their conclusions in the first place.
  • Now, a new system named SQUID arrives on the scene armed to pry open AI's black box of murky internal logic.
  • SQUID, short for Surrogate Quantitative Interpretability for Deepnets, is a computational tool created by Cold Spring Harbor Laboratory (CSHL) scientists.
  • SQUID could help biologists navigate the field more effectively, bringing them closer to their findings' true medical implications .

Genomenon Achieves Critical Milestone with Half of Clinical Exome Curated

Retrieved on: 
Thursday, June 20, 2024

ANN ARBOR, Mich., June 20, 2024 /PRNewswire-PRWeb/ -- Today, Genomenon, a genomics intelligence company, announced it reached a critical milestone in its mission to curate the human genome, having completed the curation of half of the clinical exome. With this significant curation completed, the company has formalized its Data Solutions program, with unprecedented insights across both germline and somatic variants.

Key Points: 
  • ANN ARBOR, Mich., June 20, 2024 /PRNewswire-PRWeb/ -- Today, Genomenon , a genomics intelligence company, announced it reached a critical milestone in its mission to curate the human genome, having completed the curation of half of the clinical exome.
  • The curation milestone comes on the heels of the company announcing its acquisition of the Clinical Knowledgebase (CKB) division from The Jackson Laboratory.
  • Genomenon's Curated Genomic Data includes:
    Germline Variants: Germline variants curated for inherited diseases and rare genetic disorders, following ACMG guidelines.
  • In November of 2023, it announced its first significant milestone with curating the clinical exome at the gene level.

Pew Supports 22 Researchers Leading Scientific Innovation

Retrieved on: 
Tuesday, June 18, 2024

PHILADELPHIA, June 18, 2024 /PRNewswire/ -- The Pew Charitable Trusts today announced the 22 researchers who have been selected to join the Pew Scholars Program in the Biomedical Sciences.

Key Points: 
  • PHILADELPHIA, June 18, 2024 /PRNewswire/ -- The Pew Charitable Trusts today announced the 22 researchers who have been selected to join the Pew Scholars Program in the Biomedical Sciences.
  • "Pew believes that supporting promising early-career researchers is key to scientific innovation, and for nearly 40 years our scholars have helped change the world—creating lifesaving therapies and responding to emerging health crises around the globe," said Donna Frisby-Greenwood, Pew's senior vice president for Philadelphia and scientific advancement.
  • "This class of scholars represents some of the best and brightest leading the charge, and I'm thrilled to welcome them into Pew's scientific community."
  • Scholars were chosen from 198 applicants nominated by leading academic institutions and researchers across the United States.

Epigenica Unveils Breakthrough Epigenetics Platform, Launches First Commercial ChIP-seq Kit for High-throughput, Multiplex Genome-wide Profiling

Retrieved on: 
Tuesday, June 18, 2024

EpiFinder Genome generates 192 genome-wide profiles in a fraction of the time it takes to perform 192 parallel ChIP-seq experiments.

Key Points: 
  • EpiFinder Genome generates 192 genome-wide profiles in a fraction of the time it takes to perform 192 parallel ChIP-seq experiments.
  • It offers intrinsically quantitative comparisons across as many as eight markers in up to 24 samples or independent replicates.
  • With superior barcoding capabilities, EpiFinder Genome reduces background noise and offers greater specificity compared to current state-of-the-art approaches.
  • The kit also includes an open-source, custom-designed pipeline analysis software for analyzing the vast quantitative data generated from EpiFinder Genome.

Pancreatic cancer's cellular amnesia

Retrieved on: 
Monday, June 17, 2024

Some of the pancreatic cells appear to have lost their identity.

Key Points: 
  • Some of the pancreatic cells appear to have lost their identity.
  • For years, researchers have wondered exactly how this deadly disease, known as basal-like pancreatic cancer, works.
  • Later research from CSHL Professor Christopher Vakoc found that this protein can also cause pancreatic cancer to become basal-like .
  • If researchers could one day figure out how to stop this interaction, it's possible they could prevent pancreatic cancer from going basal.

MGI Tech and SeqOne Partner to Advance End-to-end Genomic Analysis

Retrieved on: 
Monday, June 17, 2024

This collaboration between MGI and SeqOne encompasses three distinct initiatives:

Key Points: 
  • This collaboration between MGI and SeqOne encompasses three distinct initiatives:
    The collaboration between a Pathology Reference Lab in Spain, Agilent Technologies, MGI, and SeqOne aims to technically validate a routine workflow leveraging Agilent panels, Magnis lib prep automation, MGI DNBSEQ-G99, and SeqOne somaHRD, a clinically validated HRD signature solution, on 96 samples.
  • Enabling and validating SeqOne tertiary analysis solution compatible with MGI Megabolt for Germline Panels, Whole Exome and Whole Genome
    MegaBOLT bioinformatics analysis accelerator, self-developed and MPS-concentrated hardware accelerating system by MGI, is set to ensure seamless integration and compatibility with SeqOne's AI-powered variants identification and analysis solution.
  • This technical validation project aims to evaluate the compatibility of the SeqOne Platform with MGI sequencing data.
  • "This partnership with MGI strongly supports SeqOne's mission to broaden access to sophisticated genomic analysis, aiming to improve healthcare outcomes," said Martin Dubuc, CEO, SeqOne.

How glacier algae are challenging the way we think about evolution

Retrieved on: 
Tuesday, June 18, 2024

Though small, these algae are having a dramatic effect on the glaciers they live on.

Key Points: 
  • Though small, these algae are having a dramatic effect on the glaciers they live on.
  • During the summer melt season as liquid water forms on glaciers, blooms of purple algae darken the surface of the ice, accelerating the rate of melt.
  • Our results show that the purple colour of glacier algae, which acts like a sunscreen, was generated by new genes involved in pigment production.
  • Our genetic analysis suggests that the evolution of this purple pigment was probably vital for several adaptations in glacier algae.

The evolution of glacier algae

  • So we wondered could this period be the force driving the evolution of glacier algae?
  • After analysing genetic data and fossilised algae, we estimated that glacier algae evolved around 520-455 million years ago.
  • This suggests that the evolution of glacier algae was not linked to the Snowball Earth environments of the Cryogenian.
  • As the origin of glacier algae is later than the Cryogenian, a more recent glacial period must have been the driver of glacial adaptations in algae.
  • Despite this, glacier algae have dramatic effects across vast ice fields when liquid water forms on glacier surfaces.

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Retrieved on: 
Thursday, June 6, 2024

Named FLiRT to reflect amino acid changes occurring in the spike protein, these Omicron subvariants are descendent from JN.1, the previously dominant strain in the US.

Key Points: 
  • Named FLiRT to reflect amino acid changes occurring in the spike protein, these Omicron subvariants are descendent from JN.1, the previously dominant strain in the US.
  • TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides.
  • TVGN 489’s peptide targets have been preserved in all previously studied COVID strains.
  • Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, show that 95% of these CTLs remain active against FLiRT variants, including KP.2, the current dominant strain.